Pioneering Astaxanthin-Tumor Cell Membrane Nanoparticles for Innovative Targeted Drug Delivery on Melanoma
Jui-Jen Chang,Yi-Chen Wang,Shu-Hui Yang,Ju-Yu Wu,Ming-Wei Chang,Hui-Min David Wang
DOI: https://doi.org/10.2147/ijn.s439476
IF: 7.033
2024-03-08
International Journal of Nanomedicine
Abstract:Jui-Jen Chang, 1, 2, &ast Yi-Chen Wang, 3, 4, &ast Shu-Hui Yang, 5, 6 Ju-Yu Wu, 7 Ming-Wei Chang, 8 Hui-Min David Wang 5, 9– 11 1 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, 40447, Taiwan; 2 Graduate Institute of Integrated Medicine, China Medical University, Taichung, 40447, Taiwan; 3 Division of Cardiology, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung City, 802, Taiwan; 4 Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, 807, Taiwan; 5 Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, 402, Taiwan; 6 Bachelor Program of Biotechnology, National Chung Hsing University, Taichung, 402, Taiwan; 7 Doctoral Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung, 402, Taiwan; 8 Nanotechnology and Integrated Bioengineering Centre, University of Ulster, Belfast, BT15 1AB, Northern Ireland, UK; 9 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan; 10 Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, 404, Taiwan; 11 Center of Applied Nanomedicine, National Cheng Kung University, Tainan, 701, Taiwan &astThese authors contributed equally to this work Correspondence: Hui-Min David Wang, Graduate Institute of Biomedical Engineering, National Chung Hsing University, No. 145, Xingda Road, South Dist, Taichung City, 402, Taiwan, Tel +886-4-22840733&num651 ; +886-935753718, Email Background: Recently, the use of the tumor or its secretions as drug carriers has gradually become popular, with the advantages of high biocompatibility and enhanced drug delivery to specific cells. Melanoma is the most malignant tumor of all skin cancers; it is the most metastatic and, therefore, the most difficult to treat. The main purpose of this study is to develop nanovesicles with tumor cell membrane secretion properties to encapsulate target substances to enhance the therapeutic effect of cancer. Methods: Astaxanthin was selected as an anticancer drug due to our previous research finding that astaxanthin has extremely high antioxidant, anti-ultraviolet damage, and anti-tumor properties. The manufacturing method of the astaxanthin nanovesicle carrier is to mix melanoma cells and astaxanthin in an appropriate ratio and then remove the genetic material and inflammatory factors of cancer cells by extrusion. Results: In terms of results, after the co-culture of astaxanthin nanovesicles and melanoma cancer cells, it was confirmed that the ability of astaxanthin nanovesicles to inhibit the growth and metastasis of melanoma cancer cells was significantly better than the same amount of astaxanthin alone, and it had no effect on normal Human cells are also effective. There was no apparent harm on normal cells, indicating the ability of the vesicles to be selectively transported. Conclusion: Our findings illustrated the potential of astaxanthin nanovesicles as an anticancer drug. Keywords: melanoma, astaxanthin, nanoparticle Graphical It is very difficult to detect melanoma at an early stage because the initial form of melanoma is no different from normal spots or moles on the skin. However, melanoma expands very fast over time, and a large number of uneven small round bumps will appear quickly on the patient's body. 1 The rapid deterioration, coupled with the poor effect of existing treatment drugs, and the high cost of treatment, make it easy for patients to ignore it and give up on treatment, resulting in mortality. It has the highest percentage among all skin cancer types. According to statistics from the Ministry of Health and Welfare, melanoma accounted for 60% of the overall skin cancer death rate in 2015. The current treatment methods for melanoma include surgery, chemotherapy, radiotherapy, and immunotherapy, but these treatments often cause strong side effects and cannot completely cure melanoma. 2,3 Modern methods use cell-targeting therapies. In nano-transportation technology, researchers will coat target drugs or proteins that promote tumor cell death into nano-drug carriers for treatment. 3–5 Relevant literature showed that making nanoscale particles from the cancer cell membrane has the potential to be used as a drug carrier, because nanoparticles have a structure similar to cell membranes (such as proteins, lipids, etc.), and can exhibit -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology